Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.P. Gisbert, X. Calvet, F. Gomollon, R. Sainz.
Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la Conferencia Española de Consenso.
Med Clin (Barc), 114 (2000), pp. 185-195
[2.]
R.H. Hunt, C.A. Fallone, A.B. Thomson.
Canadian Helicobacter pylori Consensus Conference update: infections in adults. Canadian Helicobacter Study Group.
Can J Gastroenterol, 13 (1999), pp. 213-217
[3.]
P. Malfertheiner, F. Megraud, C. O’Morain, A.P. Hungin, R. Jones, A. Axon, et al.
Current concepts in the management of Helicobacter pylori infection – the Maastricht 2–2000 Consensus Report.
Aliment Pharmacol Ther, 16 (2002), pp. 167-180
[4.]
J.A. Ducons, S. Santolaria, R. Guirao, M. Ferrero, M. Montoro, F. Gomollon.
Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer.
Aliment Pharmacol Ther, 13 (1999), pp. 775-780
[5.]
X. Calvet, J. Ducons, J. Guardiola, L. Tito, V. Andreu, F. Bory, et al.
One-week triple vs. quadruple therapy for Helicobacter pylori infection – a randomized trial.
Aliment Pharmacol Ther, 16 (2002), pp. 1261-1267
[6.]
F. Palmas, R. Pellicano, E. Massimetti, M. Berrutti, S. Fagoonee, M. Rizzetto.
Eradication of Helicobacter pylori infection with proton pump inhibitor-based triple therapy. A randomised study.
Panminerva Med, 44 (2002), pp. 145-147
[7.]
M.J. Janssen, A.H. Van Oijen, A.L. Verbeek, J.B. Jansen, W.A. De Boer.
A systematic comparison of triple therapies for treatment of Helicobacter pylori infection with proton pump inhibitor/ranitidine bismuth citrate plus clarithromycin and either amoxicillin or a nitroimidazole.
Aliment Pharmacol Ther, 15 (2001), pp. 613-624
[8.]
J.M. Lee, N.P. Breslin, D.K. Hyde, M.J. Buckley, CA. O’Morain.
Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
Aliment Pharmacol Ther, 13 (1999), pp. 489-496
[9.]
W.A. De Boer, G.N. Tytgat.
Regular review: treatment of Helicobacter pylori infection.
BMJ, 320 (2000), pp. 31-34
[10.]
G. Cammarota, R. Cianci, O. Cannizzaro, L. Cuoco, G. Pirozzi, A. Gasbarrini, et al.
Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection.
Aliment Pharmacol Ther, 14 (2000), pp. 1339-1343
[11.]
S. Di Caro, V. Ojetti, M.A. Zocco, F. Cremonini, F. Bartolozzi, M. Candelli, et al.
Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication.
Aliment Pharmacol Ther, 16 (2002), pp. 527-532
[12.]
V. Isakov, I. Domareva, L. Koudryavtseva, I. Maev, Z. Ganskaya.
Furazolidone-based triple «rescue therapy» vs. quadruple «rescue therapy» for the eradication of Helicobacter pylori resistant to metronidazole.
Aliment Pharmacol Ther, 16 (2002), pp. 1277-1282
[13.]
F. Mansour-Ghanaei, M. Fallah, A. Shafaghi.
Eradication of Helicobacter pylori in duodenal ulcer disease tetracycline & furazolidone vs. metronidazole & amoxicillin in omeprazole based triple therapy.
Med Sci Monit, 8 (2002), pp. 271-301
[14.]
G. Treiber, S. Ammon, P. Malfertheiner, U. Klotz.
Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures.
Helicobacter, 7 (2002), pp. 225-231
[15.]
W.M. Wong, B.C. Wong, H. Lu, Q. Gu, Y. Yin, W.H. Wang, et al.
One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies.
Aliment Pharmacol Ther, 16 (2002), pp. 793-798
[16.]
H. Fakheri, R. Malekzadeh, S. Merat, M. Khatibian, A. Fazel, B.Z. Alizadeh, v.s. Clarithromycin, et al.
furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.
Aliment Pharmacol Ther, 15 (2001), pp. 411-416
[17.]
D.H. Kwon, M. Lee, J.J. Kim, J.G. Kim, F.A. El Zaatari, M.S. Osato, et al.
Furazolidone – and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance.
Antimicrob Agents Chemother, 45 (2001), pp. 306-308
[18.]
H. Lu, D.Z. Zhang, P.J. Hu, Z.S. Li, X.H. Lu, X.C. Fang, et al.
Oneweek regimens containing ranitidine bismuth citrate, furazolidone and either amoxicillin or tetracycline effectively eradicate Helicobacter pylori: a multicentre, randomized, double-blind study.
Aliment Pharmacol Ther, 15 (2001), pp. 1975-1979
[19.]
R. Sotoudehmanesh, R. Malekzadeh, H. Vahedi, N.E. Dariani, A.A. Asgari, S. Massarrat, et al.
Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen.
Digestion, 64 (2001), pp. 222-225
[20.]
D.Y. Graham, M.S. Osato, J. Hoffman, A.R. Opekun, S.Y. Anderson, H.M. El Zimaity.
Furazolidone combination therapies for Helicobacter pylori infection in the United States.
Aliment Pharmacol Ther, 14 (2000), pp. 211-215
[21.]
R. Malekzadeh, R. Ansari, H. Vahedi, F. Siavoshi, B.Z. Alizadeh, M.R. Eshraghian, et al.
Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease.
Aliment Pharmacol Ther, 14 (2000), pp. 299-303
[22.]
R. Dani, D.M. Queiroz, M.G. Dias, J.M. Franco, L.C. Magalhaes, G.S. Mendes, et al.
Omeprazole, clarithromycin and furazolidone for the eradication of Helicobacter pylori in patients with duodenal ulcer.
Aliment Pharmacol Ther, 13 (1999), pp. 1647-1652
[23.]
W.Z. Liu, S.D. Xiao, Y. Shi, S.M. Wu, D.Z. Zhang, W.W. Xu, et al.
Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection.
Aliment Pharmacol Ther, 13 (1999), pp. 317-322
[24.]
S.D. Xiao, W.Z. Liu, P.J. Hu, D.H. Xia, G.N. Tytgat.
High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week.
Aliment Pharmacol Ther, 13 (1999), pp. 311-315
[25.]
A.M. Segura, O. Gutierrez, W. Otero, A. Angel, R.M. Genta, D.Y. Graham.
Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection.
Aliment Pharmacol Ther, 11 (1997), pp. 529-532
[26.]
F. Canducci, V. Ojetti, P. Pola, G. Gasbarrini, A. Gasbarrini.
Rifabutin-based Helicobacter pylori eradication «rescue therapy ».
Aliment Pharmacol Ther, 15 (2001), pp. 143
[27.]
H. Bock, H. Koop, N. Lehn, M. Heep.
Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment: preliminary experience.
J Clin Gastroenterol, 31 (2000), pp. 222-225
[28.]
F. Perri, V. Festa, R. Clemente, M. Quitadamo, A. Andriulli.
Rifabutin-based «rescue therapy» for Helicobacter pylori infected patients after failure of standard regimens.
Aliment Pharmacol Ther, 14 (2000), pp. 311-316
[29.]
J.P. Gisbert, X. Calvet, L. Bujanda, J. Pajares.
Rescue therapy with rifabutin after multiple H.pylori treatment failures.
Helicobacter, (2002),
[30.]
J. Huang, R.H. Hunt.
The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analy-sis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole.
Aliment Pharmacol Ther, 13 (1999), pp. 719-729
[31.]
M. Vallve, M. Vergara, J.P. Gisbert, X. Calvet, v.s. Single.
double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
Aliment Pharmacol Ther, 16 (2002), pp. 1149-1156
[32.]
J.P. Gisbert, L. González, X. Calvet, N. García, T. López, M. Roque, et al.
Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori.
Aliment Pharmacol Ther, 14 (2000), pp. 1319-1328
[33.]
U. Peitz, M. Sulliga, K. Wolle, A. Leodolter, U. Von Arnim, S. Kahl, et al.
High rate of post-therapeutic resistance after failure of macrolide-nitroimidazole triple therapy to cure Helicobacter pylori infection: impact of two second-line therapies in a randomized study.
Aliment Pharmacol Ther, 16 (2002), pp. 315-324
[34.]
J.P. Gisbert, L. González, X. Calvet, M. Roque, R. Gabriel, J.M. Pajares, et al.
Helicobacter pylori eradication: proton pump inhibitor vs. ranitidine bismuth citrate plus two antibiotics for 1 week-a meta-analysis of efficacy.
Aliment Pharmacol Ther, 14 (2000), pp. 1141-1150
[35.]
F.K. Chan, J.J. Sung, R. Suen, J.C. Wu, T.K. Ling, S.C. Chung.
Salvage therapies after failure of Helicobacter pylori eradication with ranitidine bismuth citrate-based therapies.
Aliment Pharmacol Ther, 14 (2000), pp. 91-95
[36.]
M.L. Martin Mir, J. Val, J. Fuentes, S. García, C. Yus, M.A. Simon, et al.
Effectiveness of the eradication of Helicobacter pylori by treatment with omeprazol, amoxicillin, and clarithromycin according to dosage and administration schedule.
Gastroenterol Hepatol, 21 (1998), pp. 432-436
[37.]
E. Garcia-Romero, A. Del Val, V. Garrigues, J. Cuquerella, M.D. Higon, M. Barrachina, et al.
Tratamiento con omeprazol, claritromicina y amoxicilina durante 6 días en pacietnes con úlcera duodenal infectados por Helicobacter pylori.
Gastroenterol Hepatol, 22 (1999), pp. 1-6
[38.]
X. Calvet, N. García, T. López, J.P. Gisbert, E. Gene, M. Roque.
A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection.
Aliment Pharmacol Ther, 14 (2000), pp. 603-609
[39.]
X. Calvet, E. Gene, T. López, J.P. Gisbert.
What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis.
Aliment Pharmacol Ther, 15 (2001), pp. 1067-1076
[40.]
B.J. Marshall, C.S. Goodwin, J.R. Warren, R. Murray, E.D. Blincow, S.J. Blackbourn, et al.
Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori.
Lancet, 2 (1988), pp. 1437-1442
[41.]
R.P. Logan, P.A. Gummett, J.J. Misiewicz, Q.N. Karim, M.M. Walker, J.H. Baron.
One week eradication regimen for Helicobacter pylori.
Lancet, 338 (1991), pp. 1249-1252
[42.]
J. Valle, K. Seppala, P. Sipponen, T. Kosunen.
Disappearance of gastritis after eradication of Helicobacter pylori. A morphometric study.
Scand J Gastroenterol, 26 (1991), pp. 1057-1065
[43.]
T.J. Borody, L.L. George, S. Brandl, P. Andrews, J. Lenne, D. Moore Jones, et al.
Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy.
Scand J Gastroenterol, 27 (1992), pp. 281-284
[44.]
D.Y. Graham, G.M. Lew, H.M. Malaty, D.G. Evans, D.J. Evans Jr., P.D. Klein, et al.
Factors influencing the eradication of Helicobacter pylori with triple therapy.
Gastroenterology, 102 (1992), pp. 493-496
[45.]
S.W. Hosking, T.K. Ling, M.Y. Yung, A. Cheng, S.C. Chung, J.W. Leung, et al.
Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer.
BMJ, 305 (1992), pp. 502-504
[46.]
F. Bazzoli.
Italian omeprazole triple therapy —a 1-week regimen.
Scand J Gastroenterol, 215 (1996), pp. 118
[47.]
G.D. Bell, K. Powell, S.M. Burridge, A. Pallecaros, P.H. Jones, P.W. Gant, et al.
Experience with «triple» anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance.
Aliment Pharmacol Ther, 6 (1992), pp. 427-435
[48.]
J. Labenz, E. Gyenes, G.H. Ruhl, G. Borsch.
Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study.
Gut, 34 (1993), pp. 1167-1170
[49.]
F. Gomollon, J.A. Ducons, M. Ferrero, C.J. García, R. Guirao, M.A. Simon, et al.
Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases.
Helicobacter, 4 (1999), pp. 222-225
[50.]
E.J. Van der Wouden, J.C. Thijs, J.G. Kusters, A.A. van Zwet, J.H. Kleibeuker.
Mechanism and clinical significance of metronidazole resistance in Helicobacter pylori.
Scand J Gastroenterol Suppl, (2001), pp. 10-14
[51.]
E.J. Van der Wouden, J.C. Thijs, A.A. Van Zwet, W.J. Sluiter, J.H. Kleibeuker.
The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis.
Am J Gastroenterol, 94 (1999), pp. 1751-1759
[52.]
X. Calvet, N. García, E. Gene, R. Campo, E. Brullet, I. Sanfeliu.
Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment.
Aliment Pharmacol Ther, 15 (2001), pp. 1061-1065
[53.]
F. Gomollon, J. Valdeperez, R. Garuz, J. Fuentes, F. Barrera, J. Malo, et al.
Análisis coste-efectividad de dos estrategias de erradicación de Helicobacter pylori resultados de un estudio prospectivo y aleatorizado en atención primaria.
Med Clin (Barc), 115 (2000), pp. 1-6
[54.]
L. Laine, R.H. Hunt, H.M.T. El Zimaity, M.S. Osato, J. Spenard.
North American randomized trial of single-triple capsule (bismuth subcitrate, metronidazole, tetracycline) plus omeprazole vs.omeprazole, amoxicillin and clarithromycin for H. pylori eradication.
Gastroenterology, 120 (2000), pp. 508A
[55.]
P.H. Katelaris, B. Crotty, R. Reiner, G. Radfor-Smith, T. Bolin, M. Korman, et al.
A randomised multicenter comparison of pantoprazole quadruple and triple therapies versus bismuth triple therapy in H. pylori positive, endoscopy negative dyspepsia.
Gastroenterology, 118 (1999), pp. 4870A
[56.]
F. Perri, M.R. Villani, V. Festa, M. Quitadamo, A. Andriulli.
Predictors of failure of Helicobacter pylori eradication with the standard «Maastricht triple therapy».
Aliment Pharmacol Ther, 15 (2001), pp. 1023-1029
[57.]
M.A. Bigard, J.C. Delchier, G. Riachi, P. Thibault, P. Barthelemy.
One-week triple therapy using omeprazole, amoxycillin and clarithromycin for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia: influence of dosage of omeprazole and clarithromycin.
Aliment Pharmacol Ther, 12 (1998), pp. 383-388
[58.]
H. Kashimura, K. Suzuki, M. Hassan, K. Ikezawa, T. Sawahata, T. Watanabe, et al.
Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection.
Aliment Pharmacol Ther, 13 (1999), pp. 483-487
[59.]
B.C. Wong, F.Y. Chang, S. Abid, Z. Abbas, B.R. Lin, C. Van Rensburg, et al.
Triple therapy with clarithromycin, omeprazole, and amoxicillin for eradication of Helicobacter pylori in duodenal ulcer patients in Asia and Africa.
Aliment Pharmacol Ther, 14 (2000), pp. 1529-1535
[60.]
M.P. Dore, D.Y. Graham, R. Mele, L. Marras, S. Nieddu, A. Manca, et al.
Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection.
Am J Gastroenterol, 97 (2002), pp. 857-860
[61.]
A. Zullo, D. Vaira, C. Ricci, V. Rinaldi, C. Hassan, V. de Francesco, et al.
A novel first-line 10-day regimen for Helicobacter pylori eradication: a large multicente study.
Gastroenterology, 122 (2002), pp. 66A
[62.]
L.R. Azagra, T.E. Gene, J.M. Bonet Simo, S.F. Sole, C. Calvet.
Benefits of treatment to eradicate Helicobacter pylori infection in patients with ulcer at a primary care center.
Aten Primaria, 25 (2000), pp. 377-382
[63.]
A. Sonnenberg, W.F. Townsend.
Costs of duodenal ulcer therapy with antibiotics.
Arch Intern Med, 155 (1995), pp. 922-928
[64.]
A. Sonnenberg, J.S. Schwartz, A.F. Cutler, N. Vakil, B.S. Bloom.
Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group.
Arch Intern Med, 158 (1998), pp. 852-860
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
